XTL Biopharmaceuticals: AGM/EGM Statements

VALLEY COTTAGE, New York, October 2  /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announces today that at its Annual General Meeting and Extraordinary General Meeting held earlier today, all the resolutions proposed to the shareholders were approved.

The cancellation of the listing of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority will take place at 8:00 am (London Time) on October 31, 2007.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL).

  Contact:

  Ron Bentsur
  Chief Executive Officer
  Tel: [phone] ext. 225


DATASOURCE: XTL Biopharmaceuticals Ltd



CONTACT:  Contact: Ron Bentsur, Chief Executive Officer, Tel:

[phone] ext. 225

Copyright